Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome.
Christodoula KourtidouKonstantinos TziomalosPublished in: Biomedicines (2023)
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. A substantial proportion of patients with PCOS are either overweight or obese, and excess body weight aggravates the hormonal, reproductive and metabolic manifestations of PCOS. In recent years, several studies evaluated the role of various pharmacological agents in the management of obesity in this population. Most reports assessed glucagon-like peptide-1 receptor agonists and showed a substantial reduction in body weight. More limited data suggest that sodium-glucose cotransporter-2 inhibitors and phosphodiesterase-4 inhibitors might also be effective in the management of obesity in these patients. In the present review, we discuss the current evidence on the safety and efficacy of these agents in overweight and obese patients with PCOS.
Keyphrases
- polycystic ovary syndrome
- insulin resistance
- body weight
- metabolic syndrome
- weight loss
- adipose tissue
- high fat diet induced
- type diabetes
- skeletal muscle
- weight gain
- end stage renal disease
- bariatric surgery
- newly diagnosed
- chronic kidney disease
- physical activity
- machine learning
- peritoneal dialysis
- pregnant women
- deep learning
- adverse drug
- patient reported